# CYP1B1 Rescue Mechanism *** ### Polydatin, Resveratrol, and the CYP1B1 Rescue Mechanism ### What is CYP1B1 and why does it matter in cancer? CYP1B1 is a cytochrome P450 enzyme with an extraordinary property: it is selectively and consistently overexpressed in virtually all human tumour types — across breast, bowel, lung, kidney, prostate, ovarian, brain, and blood cancers — while remaining largely absent from surrounding healthy tissue. This makes it one of the most reliable tumour-specific biomarkers yet identified, and it has been formally proposed as a novel therapeutic target in oncology. Originally, CYP1B1 was viewed with suspicion — it was believed to activate procarcinogens into carcinogens and was assumed to be part of why cancers were harmful. However, research led by Professor Gerry Potter at De Montfort University significantly reframed this understanding. Potter's group discovered that CYP1B1 metabolises resveratrol — a phytoalexin found in red grapes, Polygonum cuspidatum (the source of polydatin), and other plants — into piceatannol, a compound with well-established, potent anticancer activity. This finding was published in the journal Carcinogenesis in 2002 and reframed CYP1B1 not as a driver of cancer, but as a potential **rescue enzyme** — a tumour-specific metabolic tool that selectively converts certain dietary plant compounds into anti-tumour agents inside cancer cells, while leaving healthy cells unaffected. *** ### The resveratrol-to-piceatannol conversion: a targeted activation system The mechanism works as follows: * Resveratrol (derived in the body from polydatin) enters both healthy and cancerous cells * In healthy cells, CYP1B1 is largely absent. Resveratrol exerts its standard antioxidant, anti-inflammatory, and mildly anticancer effects through other pathways, but is not converted to piceatannol in meaningful amounts * In cancer cells, where CYP1B1 is overexpressed, resveratrol is enzymatically converted to piceatannol — a structurally similar stilbene with a critical additional hydroxyl group that dramatically increases its cytotoxic potency against cancer cells * Piceatannol has been shown to inhibit cell signalling pathways involved in tumour survival, including STAT3, PI3K/AKT, and NF-κB, inducing apoptosis in cancer cells while sparing normal cells This is a form of **tumour-selective bioactivation** — the cancer cell's own enzyme converts a non-toxic dietary compound into a targeted anti-cancer agent inside the tumour cell. The compound is, in effect, armed by the cancer cell itself. *** ### Why polydatin may be particularly well-positioned for this mechanism Since polydatin is the stabilised glucoside precursor of resveratrol, it delivers resveratrol bioavailability in a more stable, water-soluble, and absorption-friendly form. Once absorbed and converted to resveratrol, the CYP1B1-mediated activation to piceatannol proceeds in cancer cells in the same way. The improved oral bioavailability of polydatin — particularly in liposomal formulations — means more resveratrol reaches tissues and therefore more substrate is available for CYP1B1 to act on in tumour cells. This is a meaningful practical advantage over standard resveratrol supplementation, with its notoriously poor absorption. This mechanism also connects directly to the salvestrol research tradition. Salvestrols are a broader class of phytonutrients — including but not limited to resveratrol — that are metabolised by CYP1B1 in cancer cells to yield cytotoxic metabolites. Polydatin and its resveratrol metabolite represent the most studied and clinically discussed members of this class. The theory is that the CYP1B1 gene is switched on in mutated tumour cells as a biological fail-safe — a tumour-suppressor mechanism evolved to enable the body to selectively eliminate cancer cells using plant compounds from the diet. This remains a hypothesis under investigation, not an established clinical consensus — but it is biologically coherent and supported by the enzymatic data. *** ### A note on CYP1B1 and the fungal hypothesis Some researchers working at the intersection of the mycobiome and cancer biology — including Mark Lintern, whose **Cell Suppression Theory of Cancer** — propose that CYP1B1 overexpression in cancer cells may be driven, at least in part, by the presence of **intracellular fungal pathogens.** The argument is that CYP1B1's antifungal metabolic activity may represent an ancient, evolved cellular defence mechanism that is activated in response to intracellular fungal colonisation, and that the same enzyme that produces piceatannol from resveratrol is doing so partly as an antifungal defence. This is a hypothesis currently at the frontier of integrative oncology thinking, not yet confirmed by formal clinical research — but it is noted here because it contextualises why fungi, CYP1B1, resveratrol, and cancer hallmarks may be more tightly connected than mainstream oncology has yet acknowledged. *** **References for CYP1B1 and Resveratrol Bioactivation** The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1\ Cytochrome P450 1B1: a novel anticancer therapeutic target\ Bitter is Better — An Introduction to Salvestrols\ Cancer and Related Case Studies Involving Salvestrol and CYP1B1\ Salvestrols: A natural, targeted approach to preventing and treating cancer\ *** {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/cyp1b1-rescue-mechanism.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.